author-photo

Thomas A. Puchalski

Janssen Pharmaceutica

33

Papers

1484

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma.

2020 Clinical and Translational Science
Show All
- Source
- Cite
- Save
Citations (1)
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

2018 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (17)
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

2017 Clinical Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (41)
Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

2015 Blood
Show All
- Source
- Cite
- Save
Citations (13)
Dose selection of siltuximab for multicentric Castleman's disease.

2015 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (9)
Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

2015 Blood
Show All
- Source
- Cite
- Save
Citations (2)
A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

2015 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (87)
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects

2014 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (3)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

2014 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (233)
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma

2014 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (11)